Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02244658 | Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia | unknown | Phase 3 | 80 | Shandong UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT02698124 | Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice(PURPLE-D) | unknown | — | 136 | Ulsan University HospitalOTHER | 1 | Mar 7, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33(CART33) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01277484 | Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML(PODAC) | unknown | Phase 1 | 19 | Seoul St. Mary's HospitalOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation(SCRAMBLE) | unknown | Phase 1 | 12 | University of SydneyOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01284712 | Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) | unknown | — | 27 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT01802450 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase(DASAPOST) | unknown | Phase 2 | 18 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02511340 | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | unknown | Phase 2 | 167 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible(TCP-AML) | unknown | Phase 1 / Phase 2 | 16 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT02489929 | Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | unknown | N/A | 35 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jul 3, 2015 | clinicaltrials |
| NCT01369368 | Treatment of Acute Leukemia Relapse After Allotransplantation | unknown | Phase 1 / Phase 2 | 20 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00885508 | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q(GFM-Chimio-Rev) | unknown | Phase 2 | 85 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01889407 | Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients | unknown | — | 94 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT02389920 | Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib | unknown | Phase 4 | 40 | Samsung Medical CenterOTHER | 0 | Mar 17, 2015 | clinicaltrials |
| NCT01298934 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis | unknown | Phase 1 / Phase 2 | 22 | Ronald HoffmanOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT02275663 | Azacytidine Plus FLAG for Relapsed or Refractory AML | unknown | Phase 2 | 37 | King Fahad Medical CityOTHER_GOV | 1 | Jan 6, 2015 | clinicaltrials |
| NCT02317159 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | unknown | Phase 4 | 90 | CttqINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
| NCT01800643 | Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | Phase 2 / Phase 3 | 100 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00668421 | CEP-701 (Lestaurtinib) in Myelofibrosis | unknown | Phase 1 / Phase 2 | 60 | Ronald HoffmanOTHER | 1 | Nov 26, 2014 | clinicaltrials |
| NCT02277847 | Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia | unknown | Phase 4 | 400 | Guangdong Provincial People's HospitalOTHER | 0 | Oct 29, 2014 | clinicaltrials |
| NCT02176109 | Metabolism Des LAM(LAM-ROS) | unknown | — | 80 | University Hospital, GrenobleOTHER | 1 | Jun 26, 2014 | clinicaltrials |
| NCT01587430 | 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | unknown | Phase 4 | 245 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 7, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT02072811 | Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia(PALG-AML2012) | unknown | Phase 3 | 400 | dr hab. n. med. Agnieszka WierzbowskaOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT01280786 | Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 36 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT01400074 | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib(RE-NICE) | unknown | Phase 3 | 100 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01562847 | Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib(AMICAN) | unknown | — | 125 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01564836 | Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | unknown | N/A | 50 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00242515 | T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | unknown | Phase 1 / Phase 2 | 16 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00295997 | Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia | unknown | N/A | 35 | University of California, San FranciscoOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT02024308 | AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy | unknown | Phase 4 | 62 | Changhai HospitalOTHER | 1 | Dec 31, 2013 | clinicaltrials |
| NCT00004036 | Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer | unknown | Phase 1 | 30 | The Cleveland ClinicOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00451711 | Intermittent Liposomal Amphotericin B Primary Prophylaxis | unknown | Phase 2 | 60 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01488344 | Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 140 | University Hospital MuensterOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT01307241 | RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML | unknown | — | 50 | National Institute of CancerologíaOTHER_GOV | 1 | Nov 15, 2013 | clinicaltrials |
| NCT01188330 | Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival(MLSP) | unknown | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Oct 31, 2013 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01901666 | Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission | unknown | Phase 4 | 20 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT01887561 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | unknown | Phase 2 | 100 | Kanto CML Study GroupOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT01503502 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT01816022 | Myeloproliferative Neoplasms and Bone Structure | unknown | — | 125 | University of Southern DenmarkOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT01809392 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 2 / Phase 3 | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00636922 | Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 40 | Bayside HealthOTHER_GOV | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01785953 | Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia(AML) | unknown | — | 300 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Feb 7, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2016source: clinicaltrials